secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-04-17T23:59:59+00:00
Accession:  0001837607-24-000033
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma issues $10M convertible note to Daewoong, appoints Daewoong CEO to board
--------------------------------------------------------------------------------

- Issued $10M senior secured convertible note to Daewoong on April 12, 2024, with 15.79% annual interest and maturity April 12, 2027.
- Proceeds will support late-stage clinical development of ABP-450 and general working capital.
- Appointed Seongsoo Park (CEO of Daewoong) as Class III director, expanding board from five to six members.
- Note is identical in terms to the $5M convertible note issued March 24, 2024 under the same subscription agreement.
- Mr. Park will serve until the 2026 annual meeting; he brings industry and leadership experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/0001837607-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/aeon-20240412x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer